Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rose 3.1% during trading on Friday . The company traded as high as $2.25 and last traded at $2.16. Approximately 1,286,381 shares changed hands during mid-day trading, an increase of 8% from the average daily volume of 1,188,200 shares. The stock had previously closed at $2.23.

CATB has been the subject of a number of recent research reports. Oppenheimer Holdings, Inc. cut their price objective on shares of Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a report on Tuesday, August 15th. Citigroup Inc. reiterated a “hold” rating and issued a $1.50 price objective on shares of Catabasis Pharmaceuticals in a report on Friday. HC Wainwright increased their price objective on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Catabasis Pharmaceuticals in a report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $4.00.

The stock’s market capitalization is $47.66 million. The firm’s 50 day moving average is $1.57 and its 200-day moving average is $1.57.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. Equities analysts forecast that Catabasis Pharmaceuticals, Inc. will post ($1.39) earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Virtu KCG Holdings LLC acquired a new position in shares of Catabasis Pharmaceuticals in the second quarter valued at approximately $271,000. Oppenheimer & Co. Inc. raised its position in shares of Catabasis Pharmaceuticals by 33.3% in the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 30,000 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Catabasis Pharmaceuticals in the first quarter valued at approximately $106,000. 32.90% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Catabasis Pharmaceuticals, Inc. (CATB) Stock Price Up -3.1%” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/catabasis-pharmaceuticals-inc-catb-stock-price-up-3-1/1599853.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.